Results reported here suggest that PDE3B and/or its downstream signaling partners might be important regulators of energy metabolism and inflammation in adipose tissue, and potential therapeutic targets for treating obesity, diabetes and their associated metabolic disorders. Here, PDE3B is linked to metabolic disease.